Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 7/2017

01.05.2017 | AdisInsight Report

Telotristat Ethyl: First Global Approval

verfasst von: Anthony Markham

Erschienen in: Drugs | Ausgabe 7/2017

Einloggen, um Zugang zu erhalten

Abstract

Telotristat ethyl (Xermelo™) is a peripheral tryptophan hydroxylase (TPH) inhibitor that was developed by Lexicon Pharmaceuticals, Inc. for the treatment of carcinoid syndrome. Many neuroendocrine tumours secrete serotonin (5-HT) into the blood stream, resulting in a number of symptoms, notably diarrhoea. Telotristat ethyl inhibits TPH, thereby reducing the production of 5-HT. In February 2017, telotristat ethyl was approved in the USA for the treatment of carcinoid syndrome diarrhoea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. This article summarizes the milestones in the development of telotristat ethyl leading to this first global approval.
Literatur
1.
2.
Lexicon P. Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate [media release]. 22 Oct 2014. http://​www.​lexpharma.​com.
3.
Lexicon P, Ipsen. Lexicon and Ipsen expand their licensing and commercialization agreement for telotristat etiprate to include Canada [media release]. 18 Mar 2015. http://​www.​lexpharma.​com.
4.
Lexicon Pharmaceuticals I. Lexicon Pharmaceuticals announces two agreements to finance long-term drug development strategy [media release]. 17 June 2007. http://​www.​lexpharma.​com.
5.
6.
7.
Kim JJ, Wang H, Terc JD, et al. Blocking peripheral serotonin synthesis by telotristat etiprate (LX1032/LX1606) reduces severity of both chemical- and infection-induced intestinal inflammation. Am J Physiol Gastrointest Liver Physiol. 2015;309(6):G455–65.CrossRefPubMed
8.
Oravecz T, Jhaver K, Yang QM, et al. LX1606 (Aka LX1032), a peripheral inhibitor of serotonin synthesis, alleviates development of inflammatory bowel disease in a preclinical model [abstract no. Mo2021]. Gastroenterology. 2012;142(5 Supplement 1):S722.
9.
Pappas SC, Brown P, Turnage A, et al. LX1032: a potential new therapy for chronic diarrhea in carcinoid syndrome (CS) [abstract no. 352]. Gastroenterology. 2009;136(5 Supplement 1):A56.
10.
Kulke MH, Horsch D, Caplin ME, et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. J Clin Oncol. 2017;35(1):14–23.CrossRefPubMed
11.
Pavel M, Gross D, Benavent M, et al. Efficacy and safety results of telotristat ethyl in patients with carcinoid syndrome during the double-blind treatment period of the TELECAST phase 3 clinical trial. In: North American Neuroendocrine Tumor Society Meeting. 2016.
12.
Pavel M, Benavent M, Perros P, et al. Telotristat ethyl in carcinoid syndrome: safety and efficacy results of an open-label extension of the TELECAST phase 3 clinical trial [abstract no. 1942 plus poster]. In: European Neuroendocrine Tumor Society (ENETS) Conference. 2017.
13.
Kulke MH, O’Dorisio T, Phan A, et al. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr Relat Cancer. 2014;21(5):705–14.CrossRefPubMedPubMedCentral
14.
Pavel M, Horsch D, Caplin M, et al. Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial. J Clin Endocrinol Metab. 2015;100(4):1511–9.CrossRefPubMed
15.
Kulke M, Horsch D, Caplin M, et al. Integrated placebo-controlled safety analysis from clinical studies of telotristat ethyl for the treatment of carcinoid syndrome [abstract no. 422PD]. Ann Oncol. 2016;27(Suppl 6):vi136–vi48.
Metadaten
Titel
Telotristat Ethyl: First Global Approval
verfasst von
Anthony Markham
Publikationsdatum
01.05.2017
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 7/2017
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-017-0737-x

Weitere Artikel der Ausgabe 7/2017

Drugs 7/2017 Zur Ausgabe

AdisInsight Report

Ribociclib: First Global Approval

Adis Drug Evaluation

Reslizumab in Eosinophilic Asthma: A Review

Current Opinion

Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors

Adis Drug Evaluation

Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma

Review Article

Fentanyl Formulations in the Management of Pain: An Update

Leading Article

Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases